Background: The aim of this study is to report clinical features and treatment outcome of pineal parenchymal tumors (PPTs). Methods: Between 2006-2017, medical records of 34 patients of PPTs were analyzed to study patterns of care of patients who received adjuvant radiotherapy (RT) with or without chemotherapy (CT) following surgery. Overall survival (OS) and progressionfree survival (PFS) were analyzed by Kaplan-Meier method. Results: According to WHO classification, the study comprises of 19 pineoblastomas (PB), 11 pineal parenchymal tumors of intermediate differentiation (PPTID) and 4 pineocytomas (PC). Median age at presentation was 10, 26 and 30 years, respectively. Headache was commonest symptom (77%) followed by visual disturbance. 59% underwent surgical resection and 41% had biopsy only. Median MIB labelling index of PPTIDs was 6%, whereas it was 35% in PB and 2% in PC. Spinal drop metastasis was present in 8 patients with PB and 3 patients with PPTIDs. All PBs and PPTIDs with spinal drop metastasis (2) received cranio-spinal irradiation (CSI) and adjuvant CT. The rest of the PPTIDs and PC received focal RT to the brain. The commonest regimen was a combination of carboplatin and etoposide (CE), used in 6 (32 %) PB. CE with vincristine and IT-MTX was given in patients who developed drop metastasis subsequently. At a median follow-up of 16 months, 9 (47%) patients of PB and 3 (27%) of PPTID developed recurrence in cranio-spinal axis. 5 year progression-free survival was 41%, 62% and 75%, respectively. Median overall survival (OS) was 27, 50, 18 months, and 5 year OS was 38%, 47% and 75%, respectively. Conclusions: PPTs reflect a broad spectrum of malignant potential and prognosis. PB is an aggressive tumor and requires adjuvant CSI and CT following surgery. PPTIDs are relatively rare and require meticulous pretreatment evaluation of neuraxis and knowledge of pathological factors for management. Multi-institutional cooperation in the form of prospective studies is recommended in view of rarity of tumor. Legal entity responsible for the study: AIIMS, New Delhi. Background: Retinoblastoma (RB) is an embryonic malignant tumor of retina caused by inactivation of both alleles of the RB1 tumor suppressor gene. Identifying low-level mosaic mutations in RB1 gene in blood samples is challenging. Mosaic mutations arise in early embryogenesis and require high-resolution techniques for detection. In approximately 10% of families, the initial RB1 mutation is mosaic. The ability to identify RB1 mosaicism is important for genetic counseling because mosaicism increases the risk for developing RB in the other eye, second cancers and transmitting the mutation to progeny.
Methods: Using NGS we have evaluated the spectrum and frequency of RB1 mutations mosaicism in peripheral blood of 120 patients with sporadic RB (82 unilateral and 38 bilateral). Results: In 5,8% (7/120) of patients a low-level mosaic mutation was found. The spectrum of identified mosaic RB1 mutations, the degree of mosaicism and clinical characteristics are shown in the table. Additionally, we analyzed the Sanger sequencing data from 72 blood samples from patients with sporadic RB (48 unilateral and 24 bilateral), performed earlier in our laboratory, and have not identified mosaic cases. Background: Patients with Glioblastoma Multiforme (GBM) despite standard therapy have a dismal prognosis and thus represent a significant unmet medical need. GBM has well documented systemic and local immunosuppressive mechanisms to escape immune surveillance and grow. GBM tumor cells as well as the microglia within it have a high incidence of PD-L1 surface expression which makes it more susceptible to anti-PD-L1 antagonism and ADCC through avelumab therapy. Combination of avelumab with other anticancer therapies have been shown safe and perhaps synergistic. A clinical trial looking at adding avelumab to standard therapy in patients with GBM is therefore indicated. Trial design: This is a single center, phase 2, open label, open-ended add-on, single dose study of 52 weeks duration in patients receiving standard therapy for newly diagnosed GBM. In total 30 patients who meet the entry criteria will be entered into the study within 3 weeks of finishing their last day of combined radiotherapy/temozolomide. Avelumab will be initiated concurrently with the initiation of the first 5 day, monthly cycle of temozolomide and continued for a total of 52 weeks. The study will consist of 3 different phases: Combination Phase a Monotherapy Phase and an Extended Safety Follow-up Phase. Clinical trial identification: NCT03047473. Legal entity responsible for the study: Clinique Neuro-Outaouais. 
